Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fusizone
- Development stage
- Unknown
- Lead developer
- Batterjee Pharmaceutical Factory
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
**Fusizone** is a topical fixed-dose cream manufactured by Batterjee Pharma containing **fusidic acid 2%** and **betamethasone valerate 0.1%**. Fusidic acid is a topical antibacterial that inhibits bacterial protein synthesis through elongation factor G, while betamethasone valerate is a topical corticosteroid that activates glucocorticoid receptors to reduce inflammation, erythema, swelling, and pruritus. It is indicated for inflammatory dermatoses, including eczema and dermatitis, when complicated by susceptible bacterial infection. ([sdi.sfda.gov.sa](https://sdi.sfda.gov.sa/home/Result?drugId=3942))
- Brand names
- FusizoneFusizone Cream
02
Targets
EF-G (Elongation factor G 1, mitochondrial)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on Fusizone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fusizone.